+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Is DD3 a new prostate-specific gene?

Is DD3 a new prostate-specific gene?

Anticancer Research 23(1a): 305-308

The search for new and more specific molecular markers of prostatic cancers has led, in recent years, to the identification of the DD3 gene. Using reverse transcription (RT)-PCR, we investigated DD3 gene expression in human cell lines, in blood samples from healthy men and women donors and in various neoplastic and non-neoplastic tissues from the prostate and other organs. Whereas RT-PCR analysis using primers that amplified the region spanning exons 1 and 3 yielded DD3 gene expression in all samples examined, a primer downstream to exon 4 detected the expected size DD3 band only in benign and malignant prostatic tissues. These findings indicate that the only prostate specific region of DD3 is exon 4.

(PDF emailed within 1 workday: $29.90)

Accession: 010885972

Download citation: RISBibTeXText

PMID: 12680228

Related references

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Bju International 109(11): 1627-1635, 2012

Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer 92(12): 2975-2984, December 15, 2001

Construction of a prostate specific antigen promoter-driven gene transfer vector A novel strategy for target specific gene therapy in prostate cancer. Journal of Urology 151(5 SUPPL ): 491A, 1994

Prostate-specific suicide gene therapy using the Prostate-Specific Membrane Antigen promoter and enhancer in tandem with a novel hybrid PSMA/cytosine deaminase gene. Proceedings of the American Association for Cancer Research Annual Meeting 43: 84, March, 2002

Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy. Anticancer Research 34(12): 7159-7165, 2015

Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. Journal of Urology 158(2): 502-504, 1997

Prostate cancer gene expression marker 1 (PCGEM1): a patented prostate- specific non-coding gene and regulator of prostate cancer progression. Recent Patents on Dna & Gene Sequences 3(3): 151-163, 2009

Gene silencing in androgen-responsive prostate cancer cells from the tissue-specific prostate-specific antigen promoter. Cancer Research 64(21): 7661-7663, 2004

Human prostate-specific transglutaminase gene: Promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer. Urology 54(6): 1105-1111, 1999

Prostate tissue-specific gene therapy utilizing a unique prostate specific antigen-cytomegalovirus promoter. Journal of Urology 153(4 SUPPL ): 307A, 1995

Prostate-specific suicide gene therapy using the newly discovered prostate-specific membrane antigen enhancer. Proceedings of the American Association for Cancer Research Annual Meeting (41): 380, March, 2000

PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. Journal of Biological Chemistry 275(2): 1216-1225, 2000

In vitro target specific gene therapy for prostate cancer utilizing a prostate specific antigen promoter-driven adenoviral vector. Proceedings of the American Association for Cancer Research Annual Meeting 35(0): 375, 1994